Hudson Bay Capital Management
INO icon

Hudson Bay Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Hudson Bay Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,677
Closed -$88.2K – 1491
2025
Q4 		$88.2K Buy
+50,677
New +$112K ﹤0.01% 1034

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's INO Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2026, closing a stake of 50,677 shares — an estimated $88.2K sold.

Hudson Bay Capital Management first reported a position in INO in Q4 2025 and held it in 1 quarter. The position peaked at $88.2K in Q4 2025. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 50,677 Inovio Pharmaceuticals shares in Q1 2026, an estimated $88.2K.
  • Hudson Bay Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Hudson Bay Capital Management's Inovio Pharmaceuticals position peaked at $88.2K in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.